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 1.  Introduction 
 The ubiquitin–proteasome pathway (UPP) is the main proteolytic system 
present in the nucleus and cytoplasm of all eukaryotic cells. Although this 
ATP-dependent pathway was discovered in the 1979  [1] , proteasome involvement 
was only demonstrated at the end of the 1980s  [2] . 
 Proteasome 26S is a multienzymatic complex found in all eukaryotic cells. 
The use of specific inhibitors has shown that the UPP is responsible for the 
cytoplasmatic turnover of a great variety of different cell proteins, thus, assuming 
an extremely important role in the regulation of not only a large number 
of physiologic processes, but also in the development of a great many human 
diseases. In fact, cyclins (A, B, C and D), cyclin-dependent kinase (CDK) 
inhibitors (p21 and p27), protein inhibitors (I κ B), tumor suppressors (p53), 
regulatory proteins (MDM2), oncogenes (c-fos, c-jun, c-myc, N-myc and 
β-catenine), together with anti and proapoptotic factors (Bcl-2 and Bax) are all 
proteasome targets  [3-5] . 
 Preclinical studies have shown that the use of proteasome inhibitors in 
the treatment of several tumors might represent a new possibility of improving 
anticancer therapy because of their ability to induce the process of programmed 
cell death  [6,7] . Therefore, whether natural or synthetic, they should be considered 
as a new class of potentially useful anticancer drugs  [8] . 
 Bortezomib (PS-341) is a dipeptide boronic acid able to inhibit, selectively 
and reversibly, the proteasome 26S  [8] , thus, leading to antiproliferative, 
proapoptotic and antiangiogenetic activity  [9] . This induced inhibition leads to 
the stabilization of the CDK inhibitors p21 and p27, the tumor suppressor p53, 
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the proapoptotic proteins Bid and Bax and of the 
transcription factor NF- κ B. 
 Bortezomib is generally well-tolerated by patients and, 
what is more, is able to increase the antitumoral effects of 
chemotherapy, radiotherapy and immunotherapy, without 
adding to their toxic effects  [10,11] . 
 Due to its high level of specificity, bortezomib was the 
first proteasome inhibitor to be approved by the US FDA; 
in 2003 as a third line and in 2005 as a second line therapy 
for the treatment of multiple myeloma (MM) only. 
 This review focuses on the use of bortezomib, not only in 
its therapeutic role but also, more specifically, in its biologic 
role and discusses the most recent applications of the drug 
in solid tumors, both at a preclinical and clinical level. 
 2.  The ubiquitin–proteosome pathway 
 The UPP involves two events: first, ubiquitylation and then 
degradation brought about by the proteasome. The former 
process requires intervention by the enzymes E1, E2 and 
E3, which, as soon as they are activated, bind the ubiquitin 
chain step-by-step to the target protein, thus causing its 
degradation ( Figure 1 ). All eukaryotes have many E2 and E3 
enzymes, but most eukaryotes have only one or a small 
number of distinct E1 enzymes  [12] . The ubiquitin-activating 
enzyme (E1), which binds ubiquitin by means of an 
ATP-dependent step, transfers a ubiquitin molecule to the 
ubiquitin-conjugating carrier protein (E2), which then 
interacts with the ubiquitin-protein ligase (E3) in order 
to bind the carrier protein covalently to a protein-target 
lysine. Several ubiquitin molecules are bound in this 
way, thus permitting the formation of a chain that is needed 
for recognition by the proteasome 26S. Ubiquitylation is 
a reversible process, due to the intervention of the 
deubiquitylation enzymes. The minimum length of an 
ubiquitin chain required for protein recognition is at least 
four molecules  [13] . 
 2.1  Structure of the proteasome 
 The proteasome 26S is a multienzymatic cylindrical 
complex made up of 2.5 kDa, which belongs to the 
N-terminal nucleophilic hydrolase family. It is present in the 
nucleus and in the cytoplasm of several eukaryotic cells  [14] . 
This organelle consists of a 20S tubular core (CP), able to 
trigger off catalytic activity, with the 19S regulating subunits 
(RPs) linked to each end; these are responsible for the 
recognition of the ubiquitinized proteins and for the regula-
tion of entry to the 20S core ( Figure 2 ). More specifically, 
each subunit is made up of a base and a lid. The latter is 
made up of at least nine polypeptides and is responsible for 
binding and removing the polyubiquitin chains from the 
assigned proteins so that the chains can then be recycled. 
The base consists of eight polypeptides, six of which have 
ATPase activity, which reduce the polypeptide and catalyze 
their translocation to the 20S core  [15,16] . 
 The 20S (72 kDa) is made up of four stacked rings; two 
outer rings consisting of seven  α -subunits ( α 1 –  α 7) and 
two inner ones of seven  β -subunits ( β 1 –  β 7)  [17] . Each 
inside ring presents three sites with chymotrypsin-like, 
trypsin-like and postglutamyl peptide hydrolase-like catalytic 
activity, arranged along the inside edge of the channel  [17-19] . 
The  β 5 subunit, which possesses a chymotrypsin-like 
activity, cuts the polypeptides after hydrophobic residues; 
the  β 2 subunit, with trypsin-like activity, cleaves after basic 
amino acids and, finally, the  β 1 subunit, with its post-
glutamyl peptide hydrolase-like, preferentially splits peptide 
bonds after acidic residues. Protein degradation occurs 
progressively by generating peptides of 3 – 25 amino acids, 
which are then dispersed on the outside and subsequently 
recycled by the cells  [20,21] . 
 The specific and reversible inhibition of the 
chymotrypsin-like activity of the proteasome is sufficient for 
the induction of cell cycle arrest and apoptosis, attributed 
to the inhibition of NF-κB. In particular, the inhibition 
of the chymotrypsin-like site, observed in patients treated 
with bortezomib, is sufficient to cause apoptosis of 
MM cells  [22] . 
 3.  Proteasome and cancer 
 In normal conditions, UPP is involved in maintaining the 
stability of several proteins implicated in the regulation of 
cell cycle and division, DNA repair and transcription, the 
immune response and inflammation, antigen processing, 
differentiation, cell development and in apoptosis  [23,24] . 
Among these, the proteins p21 and p27, belonging to the 
Cip/Kip family of the CDK inhibitors, prevent the forma-
tion of several different CDK–cyclin complexes and inhibit 
progression of the cell cycle. Low levels of p21 and p27, 
brought about by proteasome hyperactivity, represent a neg-
ative prognostic factor in several types of cancer. As a result, 
inhibiting action by the proteasome leads to upregulation of 
these proteins, which may lead to apoptosis in  in vitro 
tumoral cells  [25-27] . 
 Another important proteasome substrate is the p53 
tumor-suppressor protein, which play an important role in 
apoptosis induction. Proteasome inhibition gives rise to an 
increase in p53 expression and stability, thus, promoting the 
programmed death process  [28] . 
 The regulation of the NF- κ B by the proteasome is 
particularly interesting ( Figure 3 ). This consists of a 
hetero dimeric transcription complex (p50/p65), involved 
not only in the regulation of immune and inflammatory 
response but also in tumorigenesis, due to cell-growth 
stimulation, angiogenesis induction and apoptosis 
blockage  [29] . In normal conditions, NF-κB is kept inactive 
in the cytoplasm by the I κ B, whereas in conditions of cell 
stress, the I κ B becomes phosphorylated by the I κ B kinase 
complex and subsequently ubiquitinized and degraded by the 
proteasome. I κ B degradation leads to the release of NF- κ B 
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and its translocation into the nucleus. The interaction 
of NF- κ B with the DNA gives rise to the expression of 
target genes such as cytokines (IL-6), survival factors (IAPa, 
Bcl-XI9), intracellular adhesion molecules, vascular adhesion 
molecules and E-selectins ( Figure 4 )  [30] . The mechanism of 
action of NF- κ B leads to cell resistance to chemotherapy  [31,32] ; 
proteasome inhibition strong enough to prevent I κ B degra-
dation, might, therefore, be useful in avoiding chemotherapy 
resistance because it would induce apoptosis. In fact,  in vitro 
studies have shown that the presence of the super repressor 
I κ B, which is a mutated form able to resist degradation by 
the proteasome, leads to the death of myeloma cells that 
have proven resistant to melphalan. Furthermore, the 
transfection of I κ B leads to an increased response of colon 
cancer cells to 7-Ethyl-10-Hydroxycamptothecin (SN-38) 
compared with that of non-transfected cells  [32,33] . 
 Then the apoptosis activation, induced by UPP 
inhibition, makes the proteasome a new target of 
anticancer therapy  [18] . 
 4.  Bortezomib 
 Bortezomib (PS-341) is a dipeptidyl boric acid approved by 
the US FDA in 2003 for the treatment of patients with 
relapsing MM. This compound has been tested by the 
National Cancer Institute (NCI) on 60 tumoral cell lines, 
demonstrating that it has a greater possibility of action in 
several of these compared with 60,000 other compounds. 
More specifically, it has been seen that low concentrations 
of bortezomib (7 nM) are able to reduce tumor growth by 
 ∼ 50%; the injection of bortezomib directly into human 
tumors implanted into mice has shown that in 40% of the 
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 Figure 1 . Ubiquitination of a target protein for its degradation by the proteasome. A ubiquitin molecule is transfered in an 
ATP-dependent manner to the ubiquitin-activating enzyme (E1) and then to the ubiquitin-conjugating carrier protein (E2), which then 
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 Figure 2 . Protein degradation by the proteasome pathway. 
 β 1: Post-glutamyl site;  β 2: Trypsin-like site;  β 5: Chymotrypsin-like site. 
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cases there is a reduction of 70% in the volume of the 
tumoral mass  [34] . 
 Bortezomib inhibits the proteasome by interacting with a 
threonine residue present in each of the catalytic sites, but 
with an affinity that gradually decreases for the sites  β 5,  β 1 
and  β 2 ( β 5 <  β 1 <<  β 2) respectively  [35] . 
 4.1  Bortezomib and apoptosis 
 The proteasome inhibition brought about by bortezomib 
contributes to the accumulation of a series of proteic factors 
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 Figure 3 . Proteasome action on the IKB-NF-kB pathway. 
 IKB: Inhibitor of NF- κ B. 
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 Figure 4 . Principal NF- k B target genes. 
 ICAM: Intracellular adhesion molecules; VCAM: Vascular adhesion molecule. 
that play an important role in cell cycle regulation, such as 
the proapoptotic factors c-jun and p53, thereby inducing or 
increasing sensitivity to apoptosis ( Figure 5 ). p53 is able to 
induce apoptosis through both the intrinsic, or mitochon-
drial, pathway and through the extrinsic death receptor 
pathway. In the former, p53 directly or indirectly modulates 
the expression of the protein targets, which include Bax, 
Bid, Puma and Noxa, involved in permeability regulation of 
the mitochondrial membrane. The subsequent emission of 
mitochondrial proteins causes the release of cytochrome C, 
caspase activation and subsequent cell death. The extrinsic 
pathway is needed in order to accentuate apoptotic response 
and, furthermore, is mediated by activation of the death 
receptors DR4, DR5, CD95, located on the plasma mem-
brane, which inhibit the production of inhibitor of apoptosis 
proteins  [36,37] . Moreover, among the proteins accumulated 
inside the cell subsequent to proteasome inhibition, there 
are the TNF-related apoptosis-inducing ligands (TRAIL), 
which are type II transmembrane proteins able to induce 
apoptosis in various tumor cell lines ( Figure 6 )  [38] . 
The TRAIL trigger off the programmed cell death process 
by means of interaction with two receptors, death 
receptor 4 (DR4) and death receptor 5 (DR5). In more 
specific terms, the interaction of TRAIL-R1 with DR4 and 
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of TRAIL-R2 with DR5 leads to the formation of the 
death-inducing signaling complex, which is able to recruit 
the Fas-associated death domain adaptor molecule. The 
latter then recruits and activates caspases-8 and -10 in order 
to activate the proteic cascade, which is able to induce 
programmed cell death  [39] . However, caspase-8 also acti-
vates Bid, a protein of the Bcl-2 family, which translocates 
to the mitochondria and, by giving rise to its permeation, 
induces apoptosis  [40] . 
 Proteasome inhibition also causes the oxidative stress 
responsible for the activation of Jun N-terminal kinase 
(JNK), which precedes the phosphorylation of c-jun. Once 
it is activated, c-jun will form, with c-Fos, the heterodimer 
AP-1; a transcription factor involved in the regulation of 
several cell processes, such as proliferation, differentiation, 
cell death and survival, which then induce the expression of 
various genes, including c-jun, Fasl and Bim. The latter two 
will be responsible for the activation of cell death, through 
both the intrinsic and extrinsic pathways  [41] . 
 Bortezomib also activates programmed cell death by means 
of other mechanisms, such as the activation of the heat-shock 
proteins (Hsp). The combined action of geldanamycin plus 
bortezomib disrupts Hsp90 and proteasome function, 
promotes the accumulation of aggregated, ubiquitinated 
proteins and results in enhanced antitumor activity  [42-44] . 
 In a sperimental model of C-26 colon carcinoma in mice, 
the combined action of bortezomib with TNF induced a 
dysregulated response to endoplasmic reticulum (ER) stress 
leading to apoptosis of cancer cells, evidenced by caspase-3 
cleavage, p53 accumulation, increased stress-activated 
protein kinase/c-Jun N-terminal kinase (SAPK/JNK) 
phosphorylation. Therefore, the combined treatment not 
only inhibited tumor growth, but also prolonged survival of 
animals bearing the C-26 tumors  [45] . 
 In breast cancer cell lines, bortezomib reduced the activity 
of 20S tubular core in a concentration-, time- and cell 
line-dependent manner. Proteasome inhibition causes 
nucleus-to-cytoplasm relocalization of the ER and plasma 
membrane to peri nuclear lysosomes, relocalization of ErbB2, 
increased degradation and loss of ER and ErbB2 function, 
and induction of cellular apoptosis  [46] . 
 Proteasome inhibition with bortezomib may be used to 
prevent graft-versus-host disease (GVHD) and preserving, or 
possibly even promoting, graft-versus-tumor responses in 
cancer. Inflammatory cytokines produced by T cells and 
other immune cells have been shown to be critical for 
GVHD generation. Bortezomib is capable of inhibiting 
proliferation of alloreactive T cells in a dose-dependent 
manner. The suppression of GVHD may be due to a 
reduction of cytokine production concurrent with the 
induction of apoptosis of the alloreactive T cells  [47] . 
 Finally, in non-small cell lung cancer (NSCLC) cells, 
leukemia cells and head and neck squamous cell carcinoma 
(HNSCC) cells, bortezomib brings about the formation of 
species are reactive to oxygen, which, by determining the 
alteration of the mitochondrial membrane potential and the 
release of cytochrome C, are the primary cause of 
programmed cell death  [48-50] . 
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 Figure 5 . Effects of proteasome inhibition by bortezomib. Alteration of several proteins leads to apoptosis, reduction of angiogenesis, 
migration and cellular proliferation. 
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 5.  Preclinical and clinical studies 
 5.1  Preclinical studies 
 5.1.1  Bortezomib as a single agent 
 Bortezomib can be used for the treatment of several types of 
cancer because of its ability to inhibit growth and induce 
apoptosis in various cell lines of solid tumors, for example, 
carcinoma of the lung, prostate, pancreas, colorectum, breast, 
ovary, kidney, head and neck ( Table 1 ). Furthermore,  in vitro 
studies have shown that apoptosis brought about by 
bortezomib depends on p53 expression in certain cell 
lines only, such as breast or lung cancer  [51-53] but not in 
others, for instance, colorectal and prostate cancer and 
MM  [34,54-57] , as this process is not induced by a single 
protein, but rather, the percentage of pro- and antiaptotic 
factors present in the cell  [11,58] . 
 5.1.1.1  Non-small cell lung carcinoma 
 In vitro studies conducted on NSCLC H460 cells have 
shown that treatment with bortezomib causes cell cycle 
arrest at the G2–M phase and, subsequently, apoptosis 
resulting from caspase-3 activation. The exposure of this cell 
line to bortezomib is also responsible for the reduction in 
the number of cells in the G1 phase, which is dose- and 
time-dependent  [57] . Moreover, H460 cells treated with bort-
ezomib undergo a morphologic change similar to that of 
cells treated with antitubuline agents, such as paclitaxel and 
vinblastine. However, this fact is not due to the direct action 
of bortezomib on the polymerization and depolymerization 
DR4
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Caspase-10Caspase-8
Caspase-3Bid
FADD
TRAIL-R1 TRAIL-R2
DR5
Apoptosis
 Figure 6 . The extrinsic pathway of apoptosis. 
 DR: Death receptor; FADD: Fas-associated death domain; 
TRAIL: TNF-related apoptosis-inducing ligand. 
of the microtubules, but rather to its specific action on the 
proteasome, as the inhibition of this leads to the accumula-
tion of proteins which are generally short-lived  [59] . However, 
other studies conducted on the same cell lines have shown 
that bortezomib has apoptotic action through its activation 
of the JNK  [60] . 
 Studies performed on lung cancer cells (H460, H358, 
H322), have shown that the action of Bortezomib is able to 
increase the number of G2–M phase cells, by stabilizing the 
proteins p53 and p21 cip/waf-1 and cyclin B1  [61,62] . 
 When hypoxia is induced,  in vitro studies have shown an 
increase in the proapoptotic effects of bortezomib. Low 
levels of oxygen lead to increased sensitivity to bortezomib 
of lung or colon cells compared with that of cells that have 
developed in standard concentrations of oxygen  [63] . 
 5.1.1.2  Renal cancer 
 Renal cancer cells treated with bortezomib have shown a 
decrease in the expression levels of the FLICE inhibitory 
protein, a negative regulator of the TRAIL proapoptotic 
pathway, together with an increase in apoptosis  [64] . However, 
several other reports have shown that in RCC the cell death 
process is activated through the direct action of bortezomib 
on the NF- κ B factor and is dose-dependent  [65] . 
 5.1.1.3  Multiple myeloma 
 The exposure of MM cells to bortezomib has shown that 
the drug is also able to prevent the activation of caveolin-1, 
a protein involved in cell motility and migration in several 
different tissues. Its activation requires phosphorylation by 
VEGF, a cytokine that promotes angiogenesis and is one of 
the transcriptional targets of NF- κ B. This indicates that 
bortezomib is able to inhibit both cancerous cell migration 
and the process of tumor angiogenesis  [66,67] . These various 
activities have also been confirmed by experiments 
conducted on solid tumor cell lines (breast, lung, pancreas 
and ovary)  [65] . 
 5.1.1.4  Breast cancer 
 In several breast cancer cell lines and in mice bearing 
EMT-6 breast cancers a 90% reduction of tumor survival 
has been described subsequent to either a single intraperito-
neal or dose-dependently injection of bortezomib  [68,69] . 
Several other studies of MDA-MB-231 breast cancer cells 
have shown an upregulation of p27 followed by proteasome 
inhibition after the administration of bortezomib  [11,70] . 
 5.1.1.5  Pancreatic cancer 
 In mouse xenografts of pancreatic BxPc3 tumors, an 
intravenous or intraperitoneal injection of bortezomib causes 
an increase of p21 expression and inhibits tumor growth  [71] . 
 5.1.1.6  Prostate cancer 
 In human LNCaP-Pro-5 prostate cancer cell lines, high 
doses (1 µM) of bortezomib bring about the reduction of 
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the microcirculation density and of the number of growth 
factors of the vascular endothelium together with apoptosis 
activation. A reduction in microcirculation density induced 
by bortezomib has also been observed in prostate 
tumors  [72,73] . While in human PC3M-Pro4 prostate cancer 
cell lines, whereas the drug does not cause any particular 
change in microcirculation density, it does, however, induce 
an increase in tumor cell death  [73] . 
 5.1.1.7  Head and neck squamous cell carcinomas 
 In HNSCC, bortezomib plays an antitumoral role due to its 
inhibition of the prosurvival NF- κ B pathway; furthermore, 
the proteasome inhibition induced by bortezomib causes the 
release of the reactive oxygen species. These are responsible 
for the activation of apoptosis. In bortezomib-resistant 
HNSCC cells, the drug does not induce any destruction of 
cell adhesion in treated cells  [74,75] . 
 5.1.2  Bortezomib and combined treatments 
 Bortezomib brings about an increase in chemosensitivity to 
other chemotherapy drugs, thus permitting the administration 
 Table 1 . Effect of bortezomib in solid tumors 
 in vitro and  in vivo . 
 Cancer  Effect 
NSCLC Cell cycle arrest at G2–M, activation of 
caspase-3, activation of JNK, increase in p53, 
p21 cip/waf-1, cyclin B1, MDM2, tumor 
growth delay
Renal Decreased c-FLIP, Inhibits NF- κ B pathway, 
increased tumor apoptosis
Multiple 
myeloma
Inhibits caveolin-1, Inhibits of VEGF 
secretion, decreased angiogenesis and 
tumor growth
Breast Decreased tumor growth, up-regulation of p27
Colorectal Up-regulation of p27, decreased tumor growth, 
increased tumor apoptosis, enhanced cytotoxic 
effects of irinotecan, camptothecins, CPT-11 
and radiation treatment
Pancreatic Up-regulation of p21, increased tumor 
apoptosis, enhanced cytotoxic effects of 
gemcitabine, CPT-11
Prostate Decreased angiogenesis, decreased 
VEGF, increased tumor apoptosis
Head and 
neck
Decreased angiogenesis, inhibits NF- κ B 
pathway, production of ER and ROS, activation 
of caspase-9, apoptosis
Ovarian Cell–cell interaction destruction, Inhibits NF- κ B 
pathway, increased tumor apoptosis, enhanced 
cytotoxic effects of docetaxel
 c-FLIP: FLICE inhibitory protein; ER: Endoplasmic reticulum; 
JNK: c-Jun N-terminal kinase; MDM: Murine double minute; NSCLC: Non-small 
cell lung cancer; ROS: Reactive oxygen species; VEGF: Vascular endothelial 
growth factor. 
of lower doses of these in combined treatments. Cells which 
have proven resistant to doxorubicin, mitoxantrone or 
melphalan, become more treatment-sensitive in the presence 
of bortezomib  [76,77] . The administration of the drug when 
combined with irinotecan, a topoisomerase inhibitor, has 
antiproliferative and proapoptotic activity in murine xeno-
graft models of colon cancer. This combined therapy causes 
a reduction in tumor size by 94% (69) and 89% (70) 
compared with controls. Furthermore, such tumors are 
smaller when compared with tumors treated with bortezo-
mib or irinotecan as single agents. In xenograft models of 
pancreatic cancer, the use of bortezomib together with 
gemcytabine and with docetaxel in ovarian cancer brings 
about an increase in antiproliferative, proapoptotic, anti-
tumoral and antiangiogenetic activity.  In vitro studies per-
formed on melanoma cells have shown that the combined 
action of bortezomib and temozolomide has cytotoxic and 
antiproliferative effects; moreover, in  in vivo murine xeno-
grafts, a complete remission of tumors has been observed for 
> 200 days  [78] . Preclinical studies have shown that bortezo-
mib is able to sensitize tumor cells to radiotherapy. 
The combination of bortezomib with radiotherapy gives 
rise to a reduction in the growth of colon, prostate tumors 
and NSCLC  [79-81] . 
 5.2  Clinical studies in solid tumors 
 Considering the action of bortezomib in several tumor cell 
lines, many Phase I and Phase II clinical trials have explored 
its toxicity and activity in patients with different solid 
tumors. The most important results of these studies are 
summarized in  Table 2 and  Table 3 . 
 5.2.1  Phase I clinical trials 
 The first clinical trial exploring the role of bortezomib 
as a single agent in patients with advanced solid tumors 
was reported by Aghajanian  et al.  [82] . In this study, 
43 patients were treated with bortezomib doses ranging from 
0.13 – 1.56 mg/m 2 administered intravenously twice a week 
for 2 weeks, with a week rest period. The authors reported 
one partial response (PR) of 3 months duration in a patient 
with refractory NSCLC, whereas three patients had stable 
disease with a median response duration of 4 months. Grade 3 
dose-limiting toxic effects were diarrhea and sensory neuro-
toxicity but the last one was observed only in patients with 
pre-existing neuropathy. The authors concluded that the 
treatment warranted further testing in a Phase II trial, but 
they cautioned that particular care should be taken when 
treating patients with pre-existing neuropathy. 
 Phase I studies evaluated the combination of 
bortezomib with antineoplastic agents. In the first study, 
Appleman  et al.  [83] administered bortezomib in combination 
with gemcitabine to patients with advanced solid tumors. 
Thrombocytopenia was the dose-limiting toxicity and the 
maximum tolerated dose regimen was determined to be 
1.0 mg/m 2 for bortezomib and 1000 mg/m 2 for gemcitabine. 
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In the study of Albanell  et al.  [84] , bortezomib was 
administered with docetaxel to anthracycline-treated patients 
who had advanced breast carcinoma. The maximum 
tolerated dose had not been reached; however, dose-limiting 
toxicities of febrile neutropenia and neuropathy occurred in 
14% of patients. In the irinotecan–bortezomib trial by 
Ryan  et al.  [85] , the maximum tolerated dose was bortezomib 
1.3 mg/m 2 and irinotecan 125 mg/m 2 . Ten patients achieved 
stable disease. The most common grade  ≥ 3 bortezomib-
related nonhematologic adverse events were fatigue, diarrhea 
and nausea, whereas grade  ≥ 3 bortezomib-related hema-
tologic adverse events included neutropenia and thrombo-
cytopenia but they were rarely dose-limiting. Although 
these studies were primarily designed as dose-finding 
studies to assess toxicities, antitumor activity was 
also demonstrated. 
 Papandreou  et al.  [86] reported the results of a trial 
exploring the role of single agent bortezomib in advanced 
solid tumors. Of the 53 patients assessed, 48 had androgen-
independent prostate cancer and were treated with bortezo-
mib at doses ranging from 0.13 to 2 mg/m 2 , administered 
weekly for 4 weeks with a week rest period. Two patients 
had a prostate-specific antigen response and two had a 
PR in lymph nodes. The authors suggested further 
exploration of this compound in combination with 
chemotherapeutic agents as treatment for patients with 
advanced prostate cancer. 
 The role of bortezomib in the treatment of various 
pediatric solid malignancies has also been investigated 
by Blaney  et al.  [87] . Thrombocytopenia was the only 
dose-limiting toxicity but no objective responses were found. 
 Activity of bortezomib in combination with gemcitabine 
and carboplatin was reported in NSCLC by Davies  et al.  [88] . 
The maximum tolerated dose in this trial was bortezomib 
1 mg/m 2 , gemcitabine 1.000 mg/m 2 and carboplatin at an 
area under the concentration-time curve of five. Four 
patients experienced a PR and seven patients experienced 
stable disease. 
 Aghajanian  et al. recently published the results of a study 
of bortezomib and carboplatin in recurrent ovarian or 
primary peritoneal cancer  [89] . 15 patients were treated with 
six cycles of a fixed dose of carboplatin and increasing dose 
of bortezomib (from 0.75 to 1.5 mg/m 2 ), administered 
twice-weekly for 2 week cycles every 3 weeks. There was no 
hematologic dose-limiting toxicity at a dose of 1.5 mg/m 2 . 
The overall response rate was 47%, with two complete 
responses (CRs) and five PRs, including one CR in a patient 
with platinum-resistant disease. The recommended dose of 
bortezomib administered in combination with carboplatin 
(AUC 5) was 1.3 mg/m 2 . 
 At present, an on-going trial by Voortman  et al.  [90] 
is examining the efficacy of combination therapy of 
gemcitabine, cisplatin and bortezomib in advanced 
solid tumor patients in first-line treatment. In the first 
10 patients evaluated, there were four PRs (two bladder, 
two NSCLC). The most common grade 3 and 4 toxicity 
was neutropenia. 
 Moreover, Hamilton  et al.  [91] treated 40 patients with 
solid tumors or lymphomas using an intermittent schedule 
with bortezomib doses ranging from 0.25 to 1.9 mg/m 2 
on day 1 and 4, every 2 weeks. Dose-limiting toxicity was 
evident at the 1.75 and 1.9 mg/m 2 dose levels and was 
more frequent in patients receiving individual doses 
> 3 mg/m 2 . Peripheral neuropathy represented the principal 
dose-limiting toxicity and occurred in patients who received 
higher dosages and in those previously treated with 
neurotoxic agents. Other dose-limiting toxic effects included 
diarrhea, fatigue and thrombocytopenia. Reversible inhibi-
tion of 20S proteasome activity was dose-dependent, and 
treatment was more beneficial when administered as total 
dose (mg) per fraction rather than in mg/m 2 . Although the 
authors did not state whether CRs or PRs were obtained, 
they observed antitumor activity in patients with melanoma, 
NSCLC and RCC. 
 At the American Society of Clinical Oncology 2007 
meeting, the results of a Phase I study combining vorinostat 
(a histone deacetylase inhibitor) with bortezomib were 
presented. Subjective and objective evidence of clinical 
activity has been observed in patients with refractory solid 
tumors  [92] . The association of bortezomib with topotecan 
has been explored by GQ Chen  et al. in a Phase I study 
including refractory cancer patients. This association has 
demonstrated to be feasible and well-tolerated. An expanded 
cohort at this dose will examine efficacy of this combination 
in patients with small cell cancers  [93] . A Phase I study of 
bortezo mib in combination with 5FU/LV plus oxaliplatin in 
patients with advanced colorectal cancer has been recently 
presented at last American Society of Clinical Oncology 
meeting. This combination showed a predictable toxicity 
profile and early evidence of clinical activity. The expanded 
Phase II study is ongoing  [94] . 
 5.2.2  Phase II clinical trials 
 Price  et al. published a Phase I/II trial of bortezomib plus 
docetaxel in advanced androgen-independent prostate 
cancer  [95] . In the Phase II part of the trial, patients 
were treated with docetaxel 40 mg/m 2 and two doses of 
bortezomib (1.3 or 1.6 mg/m 2 ) given on weeks 1 and 2 
every 3 weeks. No dose-limiting toxicity was observed with 
the 1.6 mg/m 2 bortezomib dose. The preliminary results 
suggested a promising activity of this combination in some 
patients previously treated with chemotherapy. 
 Contrasting results were obtained in two Phase II trials at 
single institutions conducted in patients with advanced 
RCC  [97,98] . Bortezomib was administered twice-weekly 
for 2 weeks of every 3 weeks in both the studies. In the 
first trial by Davis  et al.  [97] , bortezomib was administered at 
the dose of 1.5 mg/m 2 escalated to 1.7 mg/m 2 because 
there were not observed grade 3 or 4 toxicity, but the 
study was closed because a planned analysis on 21 – 23 
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evaluable patients showed only one objective response. 
In the other study by Kondagunta  et al.  [98] , the first 25 
of the 37 patients enrolled were treated with a dose of 
bortezomib of 1.5 mg/m 2 , subsequently decreased to 
1.3 mg/m 2 because of toxicity. Of the 37 assessable patients, 
the best response was a PR in four patients (11%), lasting 
8 – 20 months, whereas stable disease was achieved 
in 14 patients (38%). 
 Shah  et al.  [96] evaluated the use of single agent bortez-
omib in patients with metastatic neuroendocrine tumors but 
no objective responses were reached and the median period 
of stable disease observed was very short. Mackay  et al.  [101] 
also did not find any objective response in patients with 
metastatic colorectal cancer treated with bortezomib alone. 
Markovic  et al.  [102] evaluated patients with metastatic malig-
nant melanoma treated with bortezomib alone. Response 
rate in this study was also 0% and only six patients achieved 
stable disease. Therefore, combination therapy was strongly 
recommended in all these studies. 
 Multiple clinical studies in patients with NSCLC were 
initiated based on promising preclinical and Phase I clinical 
data. Fanucchi  et al.  [99] investigated the safety and efficacy 
of bortezomib monotherapy compared with the combina-
tion of bortezomib and docetaxel in patients with advanced 
NSCLC. At interim analysis, bortezomib demonstrated 
activity both alone and combined with docetaxel. In fact 
10.3% of patients treated with bortezomib alone reached 
PRs and stable disease was achieved in 17.2% of them. 
Combination therapy was also more effective with 16.1% of 
PRs and 45.2% of stable disease. Promising findings of 
bortezomib alone in patients with advanced NSCLC were 
also reported in an ongoing trial by Stevenson  et al.  [100] . 
Numerous other clinical trials are being conducted at 
present to investigate the potential of bortezomib in the 
treatment of NSCLC. Alberts  et al.  [103] investigated the 
efficacy of bortezomib monotherapy compared with 
the combination of bortezomib and gemcitabine in patients 
with metastatic pancreatic adenocarcinoma. The response 
rate for patients receiving combination therapy was 10%, 
the same as that expected for gemcitabine alone. For this 
reason, the authors concluded that there is not a role for 
bortezomib in metastatic pancreatic adenocarcinoma. In a 
multi-center Phase II study, Maki  et al.  [104] evaluated 
efficacy of bortezomib in 23 patients with recurrent or 
metastatic sarcoma. Bortezomib had minimal activity as a 
single agent in this setting of patients with only a PR. These 
researchers concluded that bortezomib should be investi-
gated in combination with agents with demonstrated 
preclinical synergy. In a Phase II study, bortezomib has been 
studied in combination with gemcitabine and carboplatin in 
114 chemonaive stage IV and selected stage IIIB NSCLC 
patients. A total of 20% had a PR and 66% a stable disease. 
At a median follow-up of 13 months, progression free and 
median survival times were 5 and 11 months respectively. 
These results are encouraging and deserve further randomized 
clinical trials  [105] . Yang  et al.  [106] evaluated bortezomib 
monotherapy in patients with metastatic breast cancer. 
Also in this case, no objective responses were reached. For 
this reason, the future development of this agent for 
the treatment of breast cancer should be considered in 
combination with other antitumor agents. 
 Recently, Ocean  et al.  [107] presented a study enrolling 
patients with advanced gastric adenocarcinomas, randomized 
to bortezomib monotherapy or to the combination of 
bortezo mib and irinotecan. Monotherapy with bortezomib 
reached a 9% response rate, whereas the combination 
reached a 44% of response rate. Considering that the 
response rate for irinotecan monotherapy is 14 – 20%, 
researchers concluded that further studies are warranted in 
gastric cancer patients. A Phase I/II trial was initiated to 
evaluate the combination of capecitabine and bortezomib in 
heavily pretreated patients with metastatic breast cancer 
(taxane and/or anthracycline resistant). Patients were treated 
with bortezomib (1.0 – 1.3 mg/m 2 ; days 1, 4, 8 and 11) 
and capecitabine (1.500 – 2.500 mg/m 2 , days 1 – 14) in 
3 week intervals. The maximum tolerated doses were 
bortezomib 1.3 mg/m 2 and capecitabine 2500 mg/m 2 . 
Dose-limiting toxicities were Grade 3 stomatitis in 1 out of 
6 patients and Grade 3 diarrhea in 1 out of 6 patients. In 
the 21 patients treated at the maximum tolerated doses, risk 
ratio was 17.6% and 47% of patients had stable diease. 
These activity results are promising  [108] . 
 Preclinical studies demonstrated that bortezomib exerts 
activity against several B cell malignancies by inducing 
apoptosis and sensitizing tumor cells to radiation or 
chemotherapy. Based on these results, clinical trials have 
been conducted with bortezomib in B cell non-Hodgkin’s 
lymphoma. In these studies, bortezomib presented a good 
safety profile and showed promising clinical activity. Mantle 
cell lymphoma appeared significantly more sensitive to bortezo-
mib than other non-Hodgkin’s lymphomas. Bortezomib 
could, in the near future, play a promising role in the 
treatment of B cell non-Hodgkin’s lymphoma  [109-111] . On 
the other hand, bortezomib has no single agent activity in 
relapsed/refractory classical Hodgkin lymphoma  [112] . 
 6.  Expert opinion 
 The proteasome plays a central role in regulation of the cell 
cycle, proliferation, cell death, angiogenesis, metastasis and 
resistance to chemotherapy and radiation therapy. Results 
from cell culture systems, animal tumor models and early 
clinical studies, suggest that proteasome inhibition repre-
sents a new therapeutic target for human cancers. Bortezomib 
is the first agent of this novel class to enter clinical trials and 
its antitumor activity has been reported from preclinical 
investigations in a variety of tumor models. Preclinical 
studies suggest that bortezomib has a unique mechanism of 
action and may display selective targeting of malignant cells 
over normal cells. Furthermore, these studies suggest 
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that bortezomib may overcome resistance of cancer cells to 
standard chemotherapy agents and radiation therapy in 
patients with relapsed or refractory disease, acting synergi-
cally with them. In some diseases, like MM, antitumor 
activity is significant even as a single agent, so bortezomib 
has been approved for the treatment of some patients with 
MM  [113] . Results of clinical studies in solid tumors are 
mixed. The response rates of single agent use are very low 
and appropriate combination chemotherapy should be 
evaluated in the future. In conclusion, these data collectively 
suggest that proteasome inhibition is a novel approach to 
cancer therapy that might offer a response in patients where 
more conventional chemotherapeutics have failed. At 
present, several Phase II and Phase III trials in hematologic 
malignancies and solid tumors are ongoing. Several open 
issues are yet unexplored, such as the late toxicity profile, 
the right dosage when associated with cytotoxic and/or other 
targeted therapies, the synergistic action with biologic drugs 
and the real impact on natural history of a variety of solid 
tumors. In the future, the results from clinical trials and the 
integration with pharmacogenetic data will offer the possi-
bility to better targeting bortezomib therapy, optimizing the 
combination with cytotoxic agents, radiotherapy and other 
novel anticancer therapies. 
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